[go: up one dir, main page]

WO2008136374A1 - 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物 - Google Patents

抗癌剤投与に伴う末梢神経障害抑制用医薬組成物 Download PDF

Info

Publication number
WO2008136374A1
WO2008136374A1 PCT/JP2008/058011 JP2008058011W WO2008136374A1 WO 2008136374 A1 WO2008136374 A1 WO 2008136374A1 JP 2008058011 W JP2008058011 W JP 2008058011W WO 2008136374 A1 WO2008136374 A1 WO 2008136374A1
Authority
WO
WIPO (PCT)
Prior art keywords
administration
pharmaceutical composition
anticancer agent
peripheral neuropathy
neuropathy caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/058011
Other languages
English (en)
French (fr)
Inventor
Takashi Kyoi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Priority to JP2008521731A priority Critical patent/JP4208036B1/ja
Publication of WO2008136374A1 publication Critical patent/WO2008136374A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

　本発明の目的は、主として、抗癌剤投与に伴う末梢神経障害を抑制するための医薬組成物を提供することにある。 　本発明は、（±）－１，８－ジエチル－１，３，４，９－テトラヒドロピラノ［３，４－ｂ］インドール－１－酢酸、（＋）－１，８－ジエチル－１，３，４，９－テトラヒドロピラノ［３，４－ｂ］インドール－１－酢酸及び（－）－１，８－ジエチル－１，３，４，９－テトラヒドロピラノ［３，４－ｂ］インドール－１－酢酸からなる群より選択される化合物又はその医薬上許容される塩を有効成分として含有する、抗癌剤を投与することにより生じる末梢神経障害を抑制するための医薬組成物に関するものである。
PCT/JP2008/058011 2007-04-26 2008-04-25 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物 Ceased WO2008136374A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008521731A JP4208036B1 (ja) 2007-04-26 2008-04-25 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-116616 2007-04-26
JP2007116616 2007-04-26
JP2007326744 2007-12-19
JP2007-326744 2007-12-19

Publications (1)

Publication Number Publication Date
WO2008136374A1 true WO2008136374A1 (ja) 2008-11-13

Family

ID=39943483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/058011 Ceased WO2008136374A1 (ja) 2007-04-26 2008-04-25 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物

Country Status (2)

Country Link
JP (3) JP4208036B1 (ja)
WO (1) WO2008136374A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014172846A (ja) * 2013-03-07 2014-09-22 Kyushu Univ がん化学療法剤に起因する末梢神経障害予防剤及び／又は治療剤
CN110151760A (zh) * 2019-06-06 2019-08-23 上海海洋大学 双吲哚化合物fgfc1在制备抗非小细胞肺癌药物中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2857392B1 (en) 2012-05-02 2018-06-13 Japanese Foundation For Cancer Research Small compound targeting at tacc3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544757A (en) * 1984-02-16 1985-10-01 American Home Products Corporation Process for the resolution of pyrano[3,4-b]indole-1-acetic acids
JPH0840903A (ja) * 1994-07-29 1996-02-13 Synthelabo Sa 抗癌剤により誘発される末梢神経障害を予防するための医薬組成物
WO2004043454A1 (en) * 2002-11-13 2004-05-27 Sigma-Tau Industrie Farmaceutiche Riunite Spa Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544757A (en) * 1984-02-16 1985-10-01 American Home Products Corporation Process for the resolution of pyrano[3,4-b]indole-1-acetic acids
JPH0840903A (ja) * 1994-07-29 1996-02-13 Synthelabo Sa 抗癌剤により誘発される末梢神経障害を予防するための医薬組成物
WO2004043454A1 (en) * 2002-11-13 2004-05-27 Sigma-Tau Industrie Farmaceutiche Riunite Spa Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAWAI S.: "Yakubutsu Ryoho ni Kansuru Saikin no Shinpo Sentakuteki COX-2 Sogaiyaku no Shintenkai", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 60, no. 12, 2002, pages 2370 - 2377 *
TAKAHASHI T.: "Koganzai Toyo ni yoru neuropathic pain ni Taisuru COX-2 Sogaiyaku no Rinsho Oyo", PHARMA MEDICA, vol. 24, no. 2, 2006, pages 79 - 83 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014172846A (ja) * 2013-03-07 2014-09-22 Kyushu Univ がん化学療法剤に起因する末梢神経障害予防剤及び／又は治療剤
CN110151760A (zh) * 2019-06-06 2019-08-23 上海海洋大学 双吲哚化合物fgfc1在制备抗非小细胞肺癌药物中的应用
CN110151760B (zh) * 2019-06-06 2022-02-11 上海海洋大学 双吲哚化合物fgfc1在制备抗非小细胞肺癌药物中的应用

Also Published As

Publication number Publication date
JPWO2008136374A1 (ja) 2010-07-29
JP2009167164A (ja) 2009-07-30
JP4281845B1 (ja) 2009-06-17
JP2009167163A (ja) 2009-07-30
JP4208036B1 (ja) 2009-01-14

Similar Documents

Publication Publication Date Title
WO2005112633A3 (en) Compounds and compositions for delivering active agents
MX2007007458A (es) Derivados de quinazolina para inhibir crecimiento de celulas cancerigenas y metodo para la preparacion de los mismos.
WO2007138472A3 (en) Triazolopyridazine derivatives
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
WO2008121348A3 (en) Peripheral opioid receptor antagonists and uses thereof
WO2010030704A3 (en) Antibacterial aminoglycoside analogs
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
WO2010132757A3 (en) Antibacterial aminoglycoside analogs
WO2009156951A3 (en) 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
WO2008144269A3 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
ZA200603538B (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
WO2011009714A3 (en) Benzoquinolizinium salt derivatives as anticancer agents
WO2005117895A3 (en) Compositions comprising meloxicam
WO2006042954A8 (fr) Dérivés de 2-amido-4-phenylthiazole, leur préparation et leur application en thérapeutique
WO2007092157A9 (en) 7-(1h-imidazol-4-yl) methyl) -5,6,7,8-tetrahydroquinoline
WO2007083188A3 (en) Improved process for the preparation of an optically active 5h-pyrrolo [3,4-b] pyrazine derivative
WO2005004915A3 (en) Compositions comprising meloxicam
TW200626158A (en) Naphthaline derivatives
WO2004098594A3 (en) Dosage form containing pantoprazole as active ingredient
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2007080324A3 (fr) Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008521731

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08752085

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08752085

Country of ref document: EP

Kind code of ref document: A1